Hospira

3Q Revenues: $1.0 billion (+1%)

3Q Earnings: $1.9 million (+58%)

YTD Revenues: $2.9 billion (-3%)

YTD Loss: $41.8 million (earnings were $38.9 million (YTD13)

Comments: Sales of Precedex and Specialty Injectable Pharmaceuticals (SIP) products in the U.S. offset the impact of pricing erosion of certain newer U.S. SIP products and lower device sales, primarily impacted by the ship-hold of most of the company’s infusion devices due to prior actions of various regulatory authorities. Global Specialty Injectable Pharmaceuticals revenue was $685.0 million in the quarter, up 7%. Medication Management sales were down 11% to $209.8 million. Other Pharma revenues were $113.4 million, down 1%.